Revised MRC prognostic classification based on multivariable analyses
| Cytogenetic abnormality . | Comments . |
|---|---|
| Favorable | |
| t(15;17)(q22;q21) | |
| t(8;21)(q22;q22) | Irrespective of additional cytogenetic abnormalities* |
| inv(16)(p13q22)/t(16;16)(p13;q22) | |
| Intermediate | |
| Entities not classified as favorable or adverse | |
| Adverse | |
| abn(3q) [excluding t(3;5)(q21∼25;q31∼35)], | |
| inv(3)(q21q26)/t(3;3)(q21;q26), | |
| add(5q), del(5q), −5, | |
| −7, add(7q)/del(7q), | Excluding cases with favorable karyotype† |
| t(6;11)(q27;q23), | |
| t(10;11)(p11∼13;q23), | |
| t(11q23) [excluding t(9;11)(p21∼22;q23) and t(11;19)(q23;p13)] | |
| t(9;22)(q34;q11), | |
| −17/abn(17p), | |
| Complex (≥ 4 unrelated abnormalities) |
| Cytogenetic abnormality . | Comments . |
|---|---|
| Favorable | |
| t(15;17)(q22;q21) | |
| t(8;21)(q22;q22) | Irrespective of additional cytogenetic abnormalities* |
| inv(16)(p13q22)/t(16;16)(p13;q22) | |
| Intermediate | |
| Entities not classified as favorable or adverse | |
| Adverse | |
| abn(3q) [excluding t(3;5)(q21∼25;q31∼35)], | |
| inv(3)(q21q26)/t(3;3)(q21;q26), | |
| add(5q), del(5q), −5, | |
| −7, add(7q)/del(7q), | Excluding cases with favorable karyotype† |
| t(6;11)(q27;q23), | |
| t(10;11)(p11∼13;q23), | |
| t(11q23) [excluding t(9;11)(p21∼22;q23) and t(11;19)(q23;p13)] | |
| t(9;22)(q34;q11), | |
| −17/abn(17p), | |
| Complex (≥ 4 unrelated abnormalities) |